OptiBiotix Health (GB:OPTI) has released an update.
OptiBiotix Health PLC reported a decrease in revenues by 21.3% to £276K in the first half of 2024, though the company has seen a significant increase in sales orders and a three-fold rise in e-commerce sales. The company is confident in its strategic progress, having strengthened its balance sheet with a successful share placing and partnerships for its product range targeting lifestyle-related health issues. Despite the revenue drop, OptiBiotix anticipates a strong sales performance for the remainder of the year due to its innovative first-generation products and the development of promising second-generation products like SweetBiotix®.
For further insights into GB:OPTI stock, check out TipRanks’ Stock Analysis page.
